Abstract
Hematopoietic Stem Cell Transplantation (HSCT) is considered a curative option for children with Acute Myeloid Leukemia (AML). Post-HSCT relapse in pediatric AML is associated with poor outcomes. Our ability to predict this event is limited.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have